AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04841200
Drug: Chinese medicine compound placebo combined with symptomatic treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 placebo Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules placebo for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules placebo for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules placebo for syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. The appearance, shape, color and packaging of Chinese medicine compound placebo are the same as those of drugs.~Each type of granule will be given orally, twice a day, for 52 weeks.
Trial: NCT06345898
Drug: JWK002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal administration of gene therapy vector JWK002 to one eye.
Trial: NCT05850546
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guideline-recommended corticosteroid therapy
Trial: NCT05026320
Drug: Naproxen gel
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10%, bid for 5 days (final application on morning of Day 6)
Trial: NCT05026320
Drug: Diclofenac gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.32% bid for 5 days (final application on morning of Day 6)
Trial: NCT05026320
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bid for 5 days (final application on morning of Day 6)
Trial: NCT05666960
Drug: R-3750
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic
Trial: NCT06435299
Drug: Cannabis oil
RxNorm normalized name: Cannabis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will have to take Cannabis oil (50mg/mL) twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
Trial: NCT06435299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will have to take Placebo oil twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
Trial: NCT05409183
Drug: CRD-740
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally.
Trial: NCT05409183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally.
Trial: NCT05553366
Drug: HB/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT05553366
Drug: Placebo (matched to VX-548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-548 for oral administration.
Trial: NCT05553366
Drug: Placebo (matched to HB/APAP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to HB/APAP for oral administration.
Trial: NCT05495243
Drug: ARINA-1
RxNorm normalized name: ZOSTERA MARINA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
Trial: NCT05495243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (0.9%)
Trial: NCT05873686
Drug: NXP900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXP900 is an orally administered SRC/YES1 kinase inhibitor
Trial: NCT05697406
Drug: Hyperpolarized 13C-Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
Trial: NCT05030155
Drug: cyclophosphamide/azathioprine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with FFS≥1 will receive cyclophosphamide then azathioprine
Trial: NCT05030155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with FFS=0 will receive placebo
Trial: NCT01776996
Drug: Continued Access Arm
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
Trial: NCT05142696
Drug: [68Ga]Ga-DOTA-TATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
Trial: NCT06639074
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given ID
Trial: NCT05691699
Drug: Placebo for ABBV-903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule; oral
Trial: NCT06500299
Drug: HDM1002 200 mg QD 12weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDM1002 tablets 200mg daily, 12weeks
Trial: NCT06500299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be provided
Trial: NCT05011266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo sub-lingual tablet daily
Trial: NCT02677610
Drug: MSRD-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSRD-100 is a topical gel.
Trial: NCT02677610
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle is a topical gel without the active ingredient in MSRD-100
Trial: NCT04516967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator tablet or sprinkle capsule
Trial: NCT05271708
Drug: Fespixon cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
Trial: NCT05271708
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
Trial: NCT06050109
Drug: OFS continues to use group after 5 years use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
Trial: NCT06310473
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m² po, Bid, d1-14, q3w ;
Trial: NCT05371054
Drug: VIP152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously, days 2 and 9, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
Trial: NCT06025396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose comparator
Trial: NCT05140863
Drug: HSK16149 20mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
Trial: NCT05140863
Drug: HSK16149 40mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
Trial: NCT05140863
Drug: Placebo BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally twice a day, treatment period; 12-weeks fixed dose
Trial: NCT06539455
Drug: standard anti-TB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard anti-TB treatment in line with international guidelines (isoniazid , rifampin, ethambutol, and pyrazinamide)
Trial: NCT05523895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin matching placebo
Trial: NCT05805865
Drug: Conventional Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colgate Cavity Protection
Trial: NCT05100251
Drug: WBC100 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for for 3 consecutive weeks (with QD dosing for the first 5 days of each week followed by a 2-day rest), followed by a 1-week rest period, with a 4 weeks as one cycle. The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type
Trial: NCT05100251
Drug: WBC100 BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first stage: single dose escalation according to classic 3+3 dose escalation method. 4 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for 2 consecutive weeks, followed by a 1-week rest period, with 3 weeks as one treatment cycle; The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type
Trial: NCT05161780
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
Trial: NCT05979051
Drug: SHR-1703 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1703 Placebo will be administered by Subcutaneous injection in Phase 3.
Trial: NCT04872790
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT05831345
Drug: Sufentanil Citrate
RxNorm normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
Trial: NCT05393193
Drug: DTG/ABC/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
Trial: NCT05495295
Drug: PhOx430
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standard 3 + 3 design will be followed. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.~A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval.
Trial: NCT05495295
Drug: PhOx430
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The implementation of this cohort (Step 3) was decided by the Protocol Steering Committee (PSC) based on clinical and pharmacokinetic data obtained in Steps 1 and 2. Six patients will be enrolled, who will receive PhOx430 orally thrice a day (tid) at a -6-hour interval over 12 hours for 21 days, and then, starting from day 22, four times a day (qid) at a 4-hour interval over 12 hours, continuously in cycles of 21 days. PhOx430 will be taken in single doses of 1,200 mg to patients weighing ≥ 50 kg and of 600 mg to patients weighing \< 50 kg, with no requirement for a full or empty stomach. The first patient will be observed after treatment start for at least 21 days before enrolling the following two. After the third patient is observed for 21 days after treatment start, 3 additional patients will be enrolled without waiting time between them. If the daily dose tested with the tid schedule is not deemed safe, the flat dose will be tested twice a day (bid) at a 12-hour interval.
Trial: NCT05381597
Drug: Combination cream of 5-fluorouracil and calcipotriene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply the cream to the size of the lesion extending to the 0.5 cm area of skin surrounding the lesion.twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
Trial: NCT05067998
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
Trial: NCT04426968
Drug: Hepalatide 2.1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.1 mg/day subcutaneously (s.c.) for 24 week
Trial: NCT04426968
Drug: Hepalatide 6.3mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.3mg/day subcutaneously (s.c.) for 24 week
Trial: NCT04426968
Drug: placebo 2.1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.1 mg/day subcutaneously (s.c.) for 24 week
Trial: NCT04426968
Drug: placebo 4.2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2 mg/day subcutaneously (s.c.) for 24 week
Trial: NCT04426968
Drug: placebo 6.3mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.3 mg/day subcutaneously (s.c.) for 24 week
Trial: NCT05664763
Drug: [18F]FPEB with PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radioactive tracer \[18F\]FPEB administered by bolus infusion over up to 2 hours with PET performed in the last 30 minutes of infusion with Positron emission tomography (PET) neuroimaging
Trial: NCT06800274
Drug: NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 patients were randomly assigned to NAAGA in single dose (49 mg/mL), instilled as 1 drop per eye four times daily for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
Trial: NCT06206291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo twice daily for first 4 weeks
Trial: NCT05858515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05456360
Drug: Sleep enhancement intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a medication administration will be limited to before bedtime.
Trial: NCT06021197
Drug: Placebo Cap
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo as a comparator
Trial: NCT05857384
Drug: IHL42X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IHL-42X consists of acetazolamide and dronabinol.
Trial: NCT06461429
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Trial: NCT06461429
Drug: Amoxicillin and Erythromycin
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Trial: NCT06461429
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Trial: NCT06461429
Drug: Caffeine citrate: Low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Trial: NCT06461429
Drug: Caffeine citrate: Medium dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Trial: NCT06461429
Drug: Caffeine citrate: High dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Trial: NCT06119581
Drug: LY3537982
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06119581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03651349
Drug: HK-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.
Trial: NCT03651349
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
Trial: NCT05579899
Drug: EVO101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cream
Trial: NCT05623982
Drug: GNC-038
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT06179407
Drug: MK-6552
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
Trial: NCT06179407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
Trial: NCT05096234
Drug: [ 18F]F-AraG PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
Trial: NCT06111547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.
Trial: NCT06604624
Drug: HD1916
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
Trial: NCT06177457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as tablets; QD over 14 days
Trial: NCT06544707
Drug: 0.003% AR-15512
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution administered via topical ocular instillation
Trial: NCT06321341
Drug: Vespireit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone
Trial: NCT06321341
Drug: Arlevert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate + Cinnarizine
Trial: NCT05879055
Drug: PM8002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06331845
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle
Trial: NCT06798675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06561685
Drug: LY4050784
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05012735
Drug: Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
Trial: NCT06799442
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mic fentanylwhich is also diluted to 2 ml.
Trial: NCT06382155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized powder for reconstitution
Trial: NCT05820685
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will get acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, gabapentin 300 mg every eight hours, and Tramadol 50 mg every six hours as needed for breakthrough pain
Trial: NCT06249191
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05754073
Drug: 2. Intranasal placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 IU, twice daily for 12 months in the placebo comparator arm in double-blinded phase
Trial: NCT05700448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05463432
Drug: HR19024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05757596
Drug: VSA001 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.